Introduction
Human epidermal growth factor receptor type 2 (HER2 or ErbB2) is overexpressed in 20%-30% of breast cancers as well as in a subset of ovarian carcinomas, non-small cell lung cancers, gastric and colon cancers [1] . Novel medicaments targeting HER2 based on the monoclonal antibodies (mAbs) trastuzumab and pertuzumab, and tyrosine kinase inhibitors such as lapatinib have been developed and shown significant therapeutic benefit in patients with HER2-expressing malignancies [2] [3] [4] . Moreover, these mAbs and their fragments have been evaluated in preclinical and clinical studies as potential carriers of radionuclides for diagnostic and therapeutic applications [5] [6] [7] [8] [9] .
With regard to utilizing HER2-specific mAbs for targeting radionuclides to tumors, an attractive feature of a radioiodination strategy is the availability of iodine radionuclides with diverse decay characteristics. In principle, this allows the same molecular structure and labeling chemistry to be employed for different applications including SPECT ( 123 I) and PET ( 124 I) imaging as well as β − -particle ( 131 I) and Auger electron ( 123 I, 125 I) targeted radiotherapy. However, direct radioiodination of tyrosine residues is not a suitable method for labeling internalizing mAbs such as trastuzumab due to rapid loss of Nuclear Medicine and Biology 42 (2015) [19] [20] [21] [22] [23] [24] [25] [26] [27] radioactivity from tumor cells after lysosomal degradation of the labeled protein [10] . This problem can be circumvented by the use of residualizing agents, which generate radiolabeled catabolites that are trapped within tumor cells after mAb degradation. Our approach for developing residualizing agents for the radioiodination of internalizing mAbs has focused on charged prosthetic groups, which yield labeled catabolites that are poorly transported across lysosomal/cell membranes [11] [12] [13] [14] . One of the most promising reagents derived from this strategy is N [15, 16] . Labeling of internalizing intact mAbs and fragments with Mal-D-GEEEK-[ ⁎ I]IB increased tumor retention of radioiodine by up to 4-fold compared with xenograft radioiodine accumulation levels observed when these proteins were labeled by direct radioiodination using Iodogen.
Because this prosthetic group contains a maleimide functionality, it requires generation of free sulfhydryl groups on the protein to allow the coupling reaction to proceed [15] . Treating the protein with 2-iminothiolane (Traut's reagent) is the most widely used technique for generating sulfhydryl groups and offers the advantage compared with constituent disulfide bond reduction of less disruption of protein tertiary structure [16] . Generation of sulfhydryl groups on protein generally is best performed just before reaction with the radiolabeled maleimide to avoid formation of multimeric species resultant from their oxidation back to disulfides. However, the overall time for preparation and purification of thiol-derivatized mAb, and its coupling to the radiolabeled maleimide can be up to 4 h, which is not ideal, particularly if routine use shorter-lived 123 I (t 1/2 = 13.2 h) or 211 At (t 1/2 = 7.2 h) is envisioned. On the other hand, utilization of prosthetic groups containing active NHS esters allows much faster conjugation to the lysine residues of unmodified proteins under mild conditions, an approach used successfully in the past with other residualizing agents [11, 13, 14] .
The objective of the current study was to synthesize a new residualizing agent, analogous to Mal-D-GEEEK-[ ⁎ I]IB but bearing a NHS ester to facilitate its conjugation with proteins. The usefulness of this reagent for labeling trastuzumab was investigated. In addition, trastuzumab labeled with these two residualizing agents was compared in HER2-expressing human breast carcinoma cell and xenograft models to evaluate linkage-dependent effects on in vitro and in vivo behavior.
Materials and methods

General
All chemicals of pure reagent grade quality were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise specified. All reagents used in cell culture studies were purchased from Invitrogen except where noted. No-carrier-added Na 125 I and Na 131 I in 0.1 M NaOH with specific activities of 2200 Ci/mmol and 1200 Ci/mmol, respectively, were purchased from Perkin-Elmer Life and Analytical Sciences (Boston, MA). Trastuzumab (Herceptin®, Genentech, San Francisco, CA), obtained from the Duke Cancer Institute pharmacy, was purified from excipients by ultrafiltration on a micro-spin column with a 100 kDa cut-off membrane, transferred to adequate volumes of phosphate buffer pH 8.0 or borate buffer pH 8. -D-GEEEK (Mal-D-GEEEK-TB) were synthesized as reported before [15] . Bis-N-hydroxysuccinimidyl 5-iodo-isophthalate and bis-Nhydroxysuccinimidyl 5-(tri-n-butylstannyl)isophthalate were prepared as reported [17] . Fmoc-Gly-Wang resin and Fmoc-D-Glu-(OtBu)-OH were obtained from Novabiochem (West Chester, PA).
Solid-phase peptide synthesis was carried out on a Perkin-Elmer Applied Biosystems (Foster City, CA) model 433A automated peptide synthesizer employing their Fast-Moc chemistry with HBTU activation of carboxyl groups. Mass spectra were recorded using an Agilent 1100 LC/MSD Trap for electrospray ionization (ESI) LC-MS. High-pressure liquid chromatography (HPLC) was performed using the following systems: (1) for analytical and semi-preparative HPLC of nonradioactive compounds, a Waters Model Delta 600 semi-prep system with a Model 600 controller and a Model 2487 dual wavelength absorbance detector; data were acquired using Millenium software; and (2) for radiochemical HPLC separations, a Beckman Gold HPLC system equipped with a Model 126 programmable solvent module coupled with a Model 166 NM variable wavelength detector and a Model 170 radioisotope detector; data were acquired using 32 Karat software. A Waters XTerra C18 HPLC column (4.6 × 250 mm, 5 μm), eluted at a flow rate of 1 mL/min was used for analytical and radioanalytical chromatography and a Waters Xterra C18 column (19 × 150 mm, 7 μm), eluted at 10 mL/min was used for semi-preparative chromatography. The gradient elution system consisted of deionized water (A) and acetonitrile (B), both containing 0.1% acetic acid (v/v). Solvents for HPLC were obtained as HPLC grade and degassed by ultrasonication for 15-20 min just before use. The following two gradient conditions were employed: (I) the proportion of B was increased linearly from 50% to 100% over a period of 30 min; (II) the proportion of B was held at 4% for 10 min and then linearly increased to 100% in the next 30 min.
Synthesis
D-EEEG (2)
Three side chain protected (OtBu) D-glutamic acid molecules were sequentially attached to glycine supported on Wang resin (0.1 mmol) using the automated synthesizer and Fmoc chemistry. The removal of the Fmoc group on the last D-glutamic acid was achieved by treatment with 20% piperidine in dimethylformamide (DMF) followed by several washes. Finally, the tetrapeptide was cleaved from the resin by treatment with 100:95:2. 
NHS-IB-D-EEEG (3)
A solution of D-EEEG (10.0 mg; 21.6 μmol) in 200 μL DMF was added to a solution of bis-N-hydroxysuccinimidyl 5-iodo-isophthalate (47.2 mg; 97.1 μmol) in 200 μL of 2% (v/v) triethylamine in DMF over a period of 20 min, and the homogenous mixture was stirred overnight under argon atmosphere at room temperature. The peptide was precipitated with excess cold ether, pelleted, washed several times with cold ether, and purified by preparative HPLC using conditions I to obtain a white powder 8. 
NHS-TB-D-EEEG (4)
A solution of D-EEEG (46.2 mg; 100 μmol) in 1.0 mL DMF was added to a solution of bis-N-hydroxysuccinimidyl 5-(tri-n-butylstannyl) isophthalate (236.2 mg; 363.8 μmol) in 1.5 mL of 2% (v/v) triethylamine in DMF over a period of 30 min. After stirring the homogenous mixture overnight under argon atmosphere at room temperature, the peptide was isolated and purified as above to get 12. (gradient II); t R = 28.9 min. The HPLC fractions containing the product were collected; most of the acetonitrile was removed using an argon stream and concentrated by solid-phase extraction using a Waters Sep-pak classic C18 cartridge (Milford, MA). NHS-[
131 I]IB-D-EEEG was eluted from the solid-phase cartridge with 1 mL of 1% AcOH in anhydrous acetonitrile, and the solvents from the eluate evaporated to dryness using a stream of argon. The residual radioactivity was used as such for coupling to trastuzumab.
Mal-D-GEEEK-[
125 I]IB The trialkylstannyl precursor was radioiodinated and purified by reversed-phase HPLC as reported before [15, 18] . Briefly, 40 μL of AcOH was added to dried sodium [ 125 The HPLC fractions containing the product were concentrated on a Sep-pak cartridge as described above and the labeled peptide eluted from the cartridge using 1 mL of anhydrous methanol. After evaporation of methanol, the residual radioactivity was used as such for conjugation to trastuzumab. 
125 I]IB Trastuzumab was first treated with 2-iminothiolane (Traut's reagent, Thermo Scientific) to generate free sulfhydryl groups as reported previously [18] . Briefly, 2-iminothiolane (2.8 μL; 2 mg/mL) in 0.1 M phosphate buffer (PB), pH 8.0 containing 5 mM EDTA, was added to an Eppendorf tube containing trastuzumab (154 μL; 200 μg; 1.3 mg/mL) in the same buffer, and the tube vortexed and left at room temperature for 90 min. The thiol-derivatized mAb was isolated using a micro-spin G-25 column (GE Healthcare, Piscataway, NJ) equilibrated with 0.1 M PB, pH 7.0, containing 5 mM EDTA. The isolated thiolated trastuzumab was added to a ½-dram vial containing dried Mal-D-GEEEK- [ 125 I]IB (730-1900 μCi) and the mixture incubated at room temperature for 45 min with occasional vortexing. The reaction was quenched by incubation for 15 min with iodoacetamide (10 μL; 100 mg/mL in PB/EDTA pH 7.0). The radiolabeled mAb was purified on a PD-10 column as described above.
Characterization of labeled mAbs
Protein-associated radioactivity was determined by instant thin layer chromatography (ITLC) with PBS as the mobile phase and by coprecipitation with human serum albumin (HSA) using 20% trichloroacetic acid (TCA). The immunoreactive fraction of the radiolabeled mAb conjugates was determined by a modified Lindmo method using magnetic beads coated with recombinant ErbB2/HER2 extracellular domain, or as a nonspecific control, BSA [18] . Radiolabeled mAbs were also analyzed by SDS-PAGE under non-reducing conditions as described [18] . Radioactivity distributions on the gels were measured using a Storage Phosphor System Cyclone Plus (Perkin-Elmer Life and Analytical Sciences, Downers Grove, IL) and analyzed using Optiquant software (version 5.0) provided by the manufacturer.
Binding affinity and internalization assays
HER2-expressing BT474 human breast carcinoma cells were grown in DMEM/F12 medium supplemented with 10% fetal calf serum, streptomycin (100 μg/mL), and penicillin (100 IU/mL) at 37°C in 5% CO 2 at 4°C for 2 h; to determine nonspecific binding, the assay was repeated with a 100-fold excess of trastuzumab in the wells. Cellassociated radioactivity was determined as reported before [18] , and K D values were calculated using GraphPad Prism software. Pairedlabel internalization assays were performed in 6 well plates (8 × 10 5 cells/well), at final concentration 5 × 10 −9 nM for both labeled mAb conjugates, with non-specific uptake determined by co-incubation with a 100-fold excess of trastuzumab. The cells were incubated at 4°C for 1 h, unbound radioactivity was removed, and the cells incubated with fresh medium at 37°C for various time points up to 24 h. The percentages of initially bound radioactivity that was internalized, membrane-bound, and that present in the cell culture supernatants were determined as described [18] . The fraction of radioactivity in the cell culture supernatants that was protein-associated was determined by TCA precipitation. Radioactivity levels were measured on a dual-channel 1480 Automated Gamma Counter (Perkin-Elmer Life and Analytical Sciences, Downers Grove, IL).
Paired-label biodistribution
Animal studies were performed under guidelines established by the Duke University Institutional Animal Care and Use Committee. Tumor-to-tissue ratios also were calculated.
Statistical analysis
Data are presented as mean ± SD. The statistical significance of differences in uptake between the two tracers was determined by a paired 2-tailed Student t-test using Microsoft Excel. A P value less than 0.05 was considered statistically significant.
Results and discussion
Chemical and radiochemical synthesis
The NHS-IB-D-EEEG standard and its corresponding tin precursor were synthesized as depicted in Scheme 1. The peptide D-EEEG (2), obtained by solid-phase peptide synthesis and subsequent cleavage, was conjugated with bis-N-hydroxysuccinimidyl 5-iodo-isophthalate and bis-N-hydroxysuccinimidyl 5-(tri-n-butylstannyl)isophthalate ]IB-D-EEEG is more susceptible to hydrolysis. Because water was a component of the mobile phase used for HPLC purification and subsequent solid phase extraction, hydrolysis of NHS could have occurred, which would interfere with coupling to the mAb. Coupling of NHS-activated compounds to primary amines is usually performed in slightly basic conditions such as the pH 8.5 borate buffer used in the current study. While this pH shifts the equilibrium of lysine side chain amino groups more towards the free amine versus the protonated form, accelerating the conjugation reaction, it also can facilitate the hydrolysis of NHS, which will decrease conjugation efficiency [19] . If higher conjugation efficiencies are needed in future studies with NHS-[ 131 I]IB-D-EEEG, a simple strategy that we have used in the past with other NHS ester radiohalogenation agents is to increase the concentration of the protein from the~1 mg/mL used here to at least 5 mg/mL [20, 21] . This increases the competition between protein coupling and hydrolysis, which can result in about a twofold higher yield for protein conjugation.
The specific activities of the labeled mAbs prepared in this study were 1. 
Immunoreactive fraction and binding affinity
A potential advantage of NHS-[ ⁎ I]IB-D-EEEG compared with Mal-D-GEEEK-[ ⁎ I]
IB is the possibility of offering higher immunoreactivity and binding affinity as a consequence of less modification of mAb. The NHS derivative modifies lysine residues directly; in contrast, with the maleimido agent, where lysine residues are first modified with Traut's reagent to generate sulfhydryl groups to react with the maleimido moiety of Mal-D-GEEEK-[ ⁎ I]IB. Given that the number of lysines modified by 2-iminothiolane conjugation is greater than the number of labeled prosthetic groups coupled to the mAb [12, 15] , the degree of mAb modification is greater in terms of both the number of lysines modified, and when labeled, the size of the modification that is generated. Thus, one might expect higher immunoreactivity for the antibody labeled using NHS- (Fig. 1) , a value similar to that of reported for trastuzumab directly radioiodinated with 131 I using Iodogen (2.12 nM) for the same cell line and for unlabeled trastuzumab (4.09 nM) from assays using BT474 cells [22] . These K D values suggest that both prosthetic groups modify lysines on trastuzumab in regions not directly involved in HER2 interaction. Although NHS-[ ⁎ I]IB-D-EEEG does not offer any advantage compared with Mal-D-GEEEK-[ ⁎ I]IB in terms of HER2 binding of trastuzumab after labeling, it remains to be ascertained whether this is the case for other mAbs and smaller mAb fragments, which might be more susceptible to structural alteration. (Fig. 2) . HER2-specificity of mAb uptake was confirmed by coincubation with a 100-excess of non-labeled trastuzumab, which demonstrated that non-specific uptake was less than 0.1% of added activity at all time points. As shown in Fig. 2A ]IB at 1 h, declining to 60.7% ± 6.8% and 64.9% ± 6.9% at 24 h. The decrease in intracellularly retained radioactivity with time observed for trastuzumab labeled using these two prosthetic groups is somewhat contradictory to the behavior seen earlier when other mAbs and mAb fragments were radioiodinated with Mal-D-GEEEK-[ ⁎ I]IB. A steady increase in intracellularly retained radioactivity was observed over 24 h in internalization studies performed with an anti-EGFRvIII mAb L8A4 [15] or a double mutant fragment of trastuzumab [16] in other cell lines. With an anti-HER2 nanobody and BT474M1 cells, a fairly constant level of internalized radioactivity was observed throughout the 24 h time period [18, 23] .
As for the differences between the current results and those observed in previous studies with Mal-D-GEEEK-[ ⁎ I]IB, the fact that different biomolecules and tumor cell lines were used might have contributed to differences in internalization and cellular retention of labeled entities generated after receptor binding of the mAbs/mAb fragments. One explanation for the slow decrease in intracellular radioactivity with time may be recycling of mAb-receptor complex back to the cell surface before it had been subjected to lysosomal proteolysis and labeled catabolite trapping. This recycling process has been demonstrated in studies with radiolabeled DOTA-Tyr 3 -octreotate and somatostatin receptors [24] , EGF-EGFR [25] and of direct relevance to the current work, trastuzumab-HER2 complexes [26] . As shown in Fig. 2C , the fraction of radioactivity released into cell culture supernatants increased slowly from 13.1% ± 3.9% at 1 h to 28.0% ± 4.2% at 24 h for NHS-[ (Fig. 2D) . The presence of an increasing level of radioiodine activity in cell culture media, most of which is protein associated, is consistent with the release of trastuzumab-HER2 complexes from the cell but also could reflect the presence of free trastuzumab which for some reason, did not rebind to cell surface HER2. Differentiation of these two species was not done in these experiments but will be evaluated in future studies as we have done in the past with other potential residualizing agents [14] . It is worth noting that the levels of non-protein associated radioiodine in cell culture media were significantly lower (P b 0.05) for trastuzumab labeled using NHS-[ Despite the decrease in intracellular radioactivity seen at later time points, it is important to point out that the degree of intracellular retention of radioactivity observed with trastuzumab labeled with NHS- being trapped inside cells after mAb internalization. Finally, labeling mAbs with radiometals via bifunctional chelates is generally considered to be an effective residualizing labeling strategy, at least in comparison with direct radioiodination [30] . Considering this, it is interesting to note that 111 In-DTPA-trastuzumab showed about 50%
internalization at 24 h in SKOV-3 cells [31] , a value somewhat lower than obtained with trastuzumab labeled using NHS- The HER2-expressing BT474M1 cell line [32] , a metastatic variant of the BT474 cell line, was used for xenotransplantation due to its increased tumorigenicity [33] . The percentage of the injected dose of radioiodine activity per gram (%ID/g) present in normal tissues as a function of time is presented in Table 1 . Accumulation of both radionuclides showed a similar pattern in most tissues. Radioiodine levels in stomach and thyroid (%/organ) were low indicating a low susceptibility towards in vivo deiodination for both conjugates; however, at later time points, the NHS-[ 131 I]IB-D-EEEG-mAb conjugate exhibited significantly lower uptake (P b 0.05) in these tissues that are known to accumulate free iodide. The most striking differences observed in the biodistribution of the two D-peptidetrastuzumab conjugates were observed in tumor and kidneys (Fig. 3) . Unlike the binding affinity, immunoreactivity and internalization Nonetheless, the tumor uptake observed for both radioconjugates was relatively high, reaching a maximum of 29 Re-SOCTA [22] was considerably lower, at 8.2% ± 1.6% ID/g, 16.9% ± 5.4% ID/g and 7.3% ± 1.2% ID/g, respectively at 48 h. Although comparisons with studies done in different tumor models must be done with caution, the peak tumor uptakes observed for the two D-peptidetrastuzumab conjugates in the current study also compared favorably with the results obtained with radiolabeled trastuzumab preparations evaluated in other HER2-expressing tumor models. With regard to other radioiodination approaches, the maximum tumor uptake reported for trastuzumab labeled using N-succinimidyl p-
iodobenzoate was about 16% ID/g at 24 h in NCI-N87 gastric adenocarcinoma xenografts [28] . In three studies performed in the SKOV-3 ovarian carcinoma model with trastuzumab labeled with 111 In using residualizing DTPA-derivatives as chelating agents, the tumor uptake levels observed at 24 h were 13.7% ± 0.6% ID/g [31] , 17.7% ± 1.9% ID/g [36] and about 20% ID/g [37] . Finally, in a recent study also performed in mice with SKOV-3 xenografts, tumor uptake for trastuzumab labeled with 111 In and 177 Lu labeled via the DOTA macrocycle was comparable to that measured in the current study but lower than that obtainable ( 111 In, 58.3% ± 17.2% ID/g; 177 Lu, 63.5% ± 15% ID/g at 48 h) with the newly described acyclic chelator, H 4 octapa [38] .
A potential disadvantage observed in previous studies evaluating the possible utility of Mal-D-GEEEK-[ ⁎ I]IB for protein radioiodination is that kidney radioactivity levels were higher than those resultant from the use of other labeling strategies. These differences were most striking with 15 kDa nanobodies [18, 23] , in the protein size range characterized by having high renal tubular reabsorption [39] ; however, even with 150 kDa intact mAbs [15] and a 105 kDa mAb fragment [16] , kidney activity levels were two-to threefold higher after Mal-D-GEEEK-[ ⁎ I]IB labeling compared with direct electrophilic protein iodination. A possible explanation for this behavior which has been proposed [16] is that Mal-D-GEEEK-[ ⁎ I]IB contains three glutamic acid residues that might be recognized by the EAAT3 transporter, which facilitates proximal tubular reabsorption of Lglutamic acid [40] . However, the results of the current study contradict this hypothesis because kidney levels for trastuzumab-NHS-[ The significantly lower kidney uptake and expedited renal clearance observed with NHS-[ ⁎ I]IB-D-EEEG labeling could be advantageous in reducing renal radiation dose, particularly for targeted radiotherapy, and for imaging HER2-expressing cancers in close proximity to the kidneys. It remains to be ascertained whether similar advantages will be obtainable with smaller proteins such as nanobodies, where kidney levels in excess of 100% ID/g were observed after labeling with Mal-D-GEEEK-[ ⁎ I]IB [18, 23] . The mechanisms responsible for the differential kidney uptake of proteins labeled 
